Prediction of Gastric Cancer in Intestinal Metaplasia and Atrophic Gastritis
Launched by CHINESE UNIVERSITY OF HONG KONG · Apr 7, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how to better predict the risk of developing gastric cancer in people who have certain stomach conditions called intestinal metaplasia (IM) and atrophic gastritis (AG). Researchers want to find out which specific factors, either from a medical history or tissue samples, might indicate a higher chance of developing cancer. They are also creating a special computer program that can help determine individual risks for patients with these conditions.
Anyone who is 18 years or older and has been diagnosed with atrophic gastritis or intestinal metaplasia is eligible to participate. There are no specific exclusions, meaning almost anyone fitting these criteria can join. If you decide to participate, you can expect to undergo evaluations that will help researchers learn more about how to identify those at risk for gastric cancer. This study is currently looking for participants, and your involvement could contribute to important discoveries in cancer prevention.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults \>= 18 years of age
- • Histologically proven atrophic gastritis or intestinal metaplasia (at antrum and/or body and/or angular of stomach)
- Exclusion Criteria:
- • - none
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shatin, New Territories, Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials